NP31325 Parenteral Nutrition Products

Open

Buyers

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

Value

£8,756,000

Classifications

Pharmaceutical products
Parenteral nutrition products

Tags

tender

Submission Deadline

1 month from now

Published

21 hours ago

Description

Supply of Parenteral Nutrition Products for Adult, Paediatric and Neonatal Patients within NHS Scotland.

Documents

Premium

Bypass the hassle of outdated portals. Get all the information you need right here, right now.

Contract Agreement

The official contract terms, conditions, and scopes of work.

Download
Award Notice

Details on the tender award and selected suppliers.

Download

Similar Contracts

Open

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

Published 4 days ago

Open

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

Published 4 days ago

Open

HF Trial

Imp related activities for the T3 in HF Trial

Published 4 days ago

AI Bid Assistant

Our AI-powered tool to help you create winning bids is coming soon!

View Contract Source Save Contract

Organisation

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

Body governed by public law

Zenab Ghazali

[email protected]

+44 7977806098

[email protected]

+44 1312252525

Timeline active

Publish

Bid

Evaluate

Award

Complete